Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.76 |
| ▸ | THRB | P10828 | 1/20 | 0.76 |
| ▸ | NPC1 | O15118 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 2/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.74 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.65 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.65 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.65 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.65 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.65 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10876854 | 0.83 | MAPT (0.74) | MAPTTP53RXFP1THRBNPC1 | |
| SCHEMBL496814 | 0.83 | MAPT (0.76) | MAPTTP53RXFP1THRBNPC1 | |
| SCHEMBL10664153 | 0.83 | MAPT (0.76) | MAPTTP53RXFP1THRBNPC1 | |
| SCHEMBL2885346 | 0.82 | MAPT (0.77) | MAPTTP53RXFP1THRBNPC1 | |
| SCHEMBL10685990 | 0.81 | MAPT (0.72) | MAPTTP53RXFP1NPC1RAB9A | |
| SCHEMBL10667693 | 0.81 | MAPT (0.70) | MAPTTP53RXFP1THRBNPC1 | |
| SCHEMBL2027232 | 0.80 | MAPT (0.67) | MAPTTP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10680977 | 0.80 | MAPT (0.70) | MAPTTP53RXFP1NPC1RAB9A | |
| SCHEMBL10678162 | 0.80 | MAPT (0.70) | MAPTTP53RXFP1THRBNPC1 | |
| SCHEMBL2024771 | 0.79 | MAPT (0.69) | MAPTTP53NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645756-B2 | 6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine; has histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect; for metabolic system, circulatory system or nervous system diseases | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | MSD K.K. (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1719756-A1 | NITROGENOUS FUSED HETEROAROMATIC RING DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | HRH3, HRH2, HRH4 | MAPT 3450/4885TP53 3079/4885RXFP1 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.